Home > Boards > US Listed > Biotechs > Galera Therapeutics, Inc. (GRTX)

Oh my, I see some familiar aliases here.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
PlentyParanoid Member Profile
Member Level 
Followed By 17
Posts 948
Boards Moderated 0
Alias Born 04/26/10
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 7:06:47 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/10/2020 6:04:06 AM
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire Inc. - 11/20/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/17/2020 4:07:24 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/10/2020 7:32:03 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/10/2020 7:08:45 AM
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire Inc. - 11/10/2020 7:00:00 AM
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire Inc. - 11/3/2020 8:00:00 AM
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiati... GlobeNewswire Inc. - 10/27/2020 3:00:10 PM
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419... GlobeNewswire Inc. - 10/23/2020 5:00:10 PM
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with S... GlobeNewswire Inc. - 10/22/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/7/2020 5:02:22 PM
Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer GlobeNewswire Inc. - 9/22/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/16/2020 8:08:34 AM
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 fo... GlobeNewswire Inc. - 9/16/2020 8:00:10 AM
Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire Inc. - 9/14/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2020 7:02:34 AM
Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Plac... GlobeNewswire Inc. - 9/8/2020 8:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 7:32:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 7:11:51 AM
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire Inc. - 8/10/2020 7:00:10 AM
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference GlobeNewswire Inc. - 7/30/2020 8:00:10 AM
Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally... GlobeNewswire Inc. - 7/13/2020 5:46:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/22/2020 4:53:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2020 5:48:08 PM
PlentyParanoid Member Level  Monday, 09/07/20 04:11:42 PM
Re: loanranger post# 3
Post # of 27 
Oh my, I see some familiar aliases here. Good. I can then address this rant to you, Loanranger. In the past, you have shown remarkable tolerance of my messages, even long ones.

I have, or better said, have tried to do some checking of Galera's claims found in the report from GC4419 PIIb trial for SOM. I got outright giddy when I noticed that they have included SOM incidence and duration swim-lane chart. Hah, nitwits are providing me the means to do thorough checking of ALL REPORTED VALUES. I should have known better.

Obvious sign of trouble besides missing headcounts in table 2 is that in the said table Galera reports median duration of SOM for GC4419 90 mg dose as 1.5 days. If you check the swim-lane chart you see that for 90 mg dose there is total 35 SOM incidents. Headcount for intent to treat group for 90 mg dose happens to be 76. How can one get SOM median 1.5 days when less than 50 % of subjects did ever experience it? Of course, one can't. More misery can be found in the statistical methods section:
Quote:
Duration in patients with unresolved SOM as of the last evaluation was imputed as the median duration among patients in the same treatment arm with at least that duration. For patients without observed SOM but with incomplete follow-up, duration was imputed as the median duration among patients in the same treatment arm who were free of SOM for at least that length of follow-up.


So, even if the values in table 2 are for ITT, as they should be, they are after ‘imputation’ of missing values, which I obviously don’t have access to. At this point you should exclaim (Please, do exclaim. It would make me feel better knowing you did):
“WHAAAT! Is this proper, legit, does it cut the mustard!”

Unfortunately, it does. FDA uses similar methods, especially with heavily censored data, to estimate what might be more proper values. Then, if their findings do indicate so, they may tell the applicate: “Nice try, but no cigar this time.” If FDA can use a method to approve or reject drug application, they hardly can object to applicant using it. Also, it is approved and frequent practice in academic circles.

The above means that my grand analysis plan went the usual way, into garbage. But I can squeeze something out of those swim-lanes. They probably are for subjects for which Galera had complete SOM history, before applying what I call backfilling. That would mean, according to Galera, that they should cover about 80 % of trial subjects. That would be good enough. Unfortunately, it quickly became obvious, mostly comparing with figures 2 and A1 (in appendix) that swim-lanes probably are not completely accurate even for those subjects. Oh darn!

Finally, I decided to use values that looked the most reliable (very relative term, in this context): SOM grade > 2 and grade 4 start times. And applied the least sensitive measure I could on them, that is: I calculated risk ratios.

Log-Rank risk ratio for SOM grade 4 start times:
0.56 with 95 % confidence interval [0.3 , 1.08] favoring GC4419
Log-Rank risk ratio for SOM grade > 2 start times:
0.67 with 95 % confidence interval [0.42 , 1.04] favoring GC4419
Risk ratio for SOM grade 4 incidence rates during IMR treatment (first 7 weeks):
0.53 with Miettinen-Nurminen 95 % confidence interval [0.28 , 0.98]

The last one favors GC4419 quite strongly, confidence interval does not include 1. Other confidence intervals do.

About above results I trust more numbers for grade 4 SOM. Those subjects are less likely to be lost for follow-up. They tend to be in hospital bed and in IV. Another thing: I have found that risk ratio below 0.7 in relatively sized trials is quite good indicator for successful phase 3. Of course, it is not infallible, especially with Galera data here.
So, here you are. Just remember to treat my results as you would a rabid cat – with extreme caution.

BTW: a link to the article in question. In case you don’t have it handy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881100/


"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences